TScan Therapeutics is a deeply speculative, cash-constrained biotech pivoting to preclinical in vivo TCR-T; success could unlock major upside, but technical failure, financing needs, and dilution create substantial downside.
Overview
TScan Therapeutics is a pre-commercial biotechnology company developing engineered TCR-T cancer therapies, with no marketed products and only collaboration and licensing revenue. On September 2, 2026, it pivoted away from traditional ex vivo programs to focus on preclinical in vivo TCR-T vectors for solid tumors, pausing Phase 3 ALLOHA-2 and autoimmune discovery while cutting 75% of its workforce and eliminating internal manufacturing. Its two prioritized candidates target PRAME and MAGE-A4; management aims to file an IND in Q3 2027 and begin Phase 1 in Q4 2027. The platform’s potential advantage is avoiding patient-specific manufacturing, lymphodepletion, and specialized treatment-center infrastructure, but clinical efficacy and safety of its in vivo delivery remain unproven. Q2 2026 revenue was $1.05M, down 65.8% year over year, and net loss was $30.36M, or $0.23 per share. Cash and equivalents were $100.16M at quarter-end; restructuring savings of $55M are expected to extend runway into Q4 2027, although term-loan amortization begins in Q4 2026. At $0.23, market capitalization is about $15.0M on basic shares or $29.9M fully diluted. **The investment is a binary platform bet, not an established growth business.** Near-term catalysts include Q1 2027 preclinical data, partnerships, and the targeted IND filing.